» Articles » PMID: 35169893

The Oncogenic Fusion Landscape in Pediatric CNS Neoplasms

Overview
Specialty Neurology
Date 2022 Feb 16
PMID 35169893
Authors
Affiliations
Soon will be listed here.
Abstract

Pediatric neoplasms in the central nervous system (CNS) are the leading cause of cancer-related deaths in children. Recent developments in molecular analyses have greatly contributed to a more accurate diagnosis and risk stratification of CNS tumors. Additionally, sequencing studies have identified various, often entity specific, tumor-driving events. In contrast to adult tumors, which often harbor multiple mutated oncogenic drivers, the number of mutated genes in pediatric cancers is much lower and many tumors can have a single oncogenic driver. Moreover, in children, much more than in adults, fusion proteins play an important role in driving tumorigenesis, and many different fusions have been identified as potential driver events in pediatric CNS neoplasms. However, a comprehensive overview of all the different reported oncogenic fusion proteins in pediatric CNS neoplasms is still lacking. A better understanding of the fusion proteins detected in these tumors and of the molecular mechanisms how these proteins drive tumorigenesis, could improve diagnosis and further benefit translational research into targeted therapies necessary to treat these distinct entities. In this review, we discuss the different oncogenic fusions reported in pediatric CNS neoplasms and their structure to create an overview of the variety of oncogenic fusion proteins to date, the tumor entities they occur in and their proposed mode of action.

Citing Articles

Case report: Germline mutation is associated with a giant cell glioblastoma.

Bi Y, Wan D, Chen S, Chen H, Guo L, He X Front Oncol. 2024; 14:1361928.

PMID: 39411129 PMC: 11474180. DOI: 10.3389/fonc.2024.1361928.


Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review.

Ahmed M, Sieben A, Van Genechten T, Libbrecht S, Gilis N, De Praeter M Cancers (Basel). 2024; 16(19).

PMID: 39409964 PMC: 11475864. DOI: 10.3390/cancers16193344.


The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases.

Metellus P, Camilla C, Bialecki E, Beaufils N, Vellutini C, Pellegrino E Front Oncol. 2024; 14:1382394.

PMID: 39087020 PMC: 11288828. DOI: 10.3389/fonc.2024.1382394.


Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse.

Bielamowicz K, Littrell M, Albert G, Parker L, Jayappa S, Aldape K J Neurooncol. 2024; 168(2):367-373.

PMID: 38639853 PMC: 11147842. DOI: 10.1007/s11060-024-04667-6.


Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas.

Nakashima T, Yamamoto R, Ohno M, Sugino H, Takahashi M, Funakoshi Y Brain Tumor Pathol. 2024; 41(2):50-60.

PMID: 38332448 DOI: 10.1007/s10014-023-00476-3.


References
1.
Shah N, Lankerovich M, Lee H, Yoon J, Schroeder B, Foltz G . Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC Genomics. 2013; 14:818. PMC: 4046790. DOI: 10.1186/1471-2164-14-818. View

2.
Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118(5):1739-49. PMC: 2289793. DOI: 10.1172/JCI33656. View

3.
Kohler M, Roring M, Schorch B, Heilmann K, Stickel N, Fiala G . Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants. EMBO J. 2015; 35(2):143-61. PMC: 4718462. DOI: 10.15252/embj.201592097. View

4.
Choubey L, Collette J, Smith K . Quantitative assessment of fibroblast growth factor receptor 1 expression in neurons and glia. PeerJ. 2017; 5:e3173. PMC: 5398288. DOI: 10.7717/peerj.3173. View

5.
Gao Q, Liang W, Foltz S, Mutharasu G, Jayasinghe R, Cao S . Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018; 23(1):227-238.e3. PMC: 5916809. DOI: 10.1016/j.celrep.2018.03.050. View